ZYME

Zymeworks has pivoted from a cash-burning platform company into a royalty-and-asset aggregator anchored by zanidatamab (Ziihera), which is already approved and throwing off royalties and milestones via partners Jazz, BeOne and J&J. The investment case got materially de-risked in late 2025: the Phase 3 HERIZON-GEA-01 trial hit, showing a ~35% reduction in risk of progression or death versus trastuzumab+chemo in first-line HER2+ GEA regardless of PD-L1 status, positioning Ziihera as a potential standard of care. That shows up in the numbers — FY2025 revenue grew 38.9% to $106M, the net loss narrowed to -$81.1M from -$123M, and operating cash burn improved 70% to just -$33M. The balance sheet is genuinely strong for a biotech: only $78M of total liabilities against $269M of equity (0.29x leverage), and MD&A discloses $270.6M of total cash resources (cash, equivalents and marketable securities) — note the $41.2M 'cash & equivalents' XBRL tag understates true liquidity. Management even bought back $41.7M of stock, a rare capital-return signal in this sector.

The problem is price and quality of earnings. At $24.10 the market cap is $1.78B, or 16.8x revenue — and that revenue is lumpy and partner-dependent (it swung from $412M in FY2022 on an upfront to ~$76M in FY2023-24 before this year's royalty-driven rebound). The company is still structurally unprofitable (-87.3% operating margin, -30.2% ROE, a -$953M accumulated deficit) and explicitly expects continued operating losses in the near-to-medium term. The wholly-owned pipeline (ZW191, ZW251, multispecific ZW209/ZW1528) is early — Phase 1 and IND-stage — and management says advancing several ADC programs is contingent on finding partners or external funding, so the equity story rests heavily on the zanidatamab royalty stream and the unproven aggregation strategy that the 10-K itself flags as its top risk.